Brief: Anpac Bio-Medical Science - Experienced Strong Demand For Paid Tests Based On Cancer Differentiation Analysis Technology Technology In Q1 Of 2021
16/04/2021 21:20
April 16 (Reuters) - AnPac Bio-Medical Science Co Ltd
ANPC.O :
* ANPAC BIO-MEDICAL SCIENCE - EXPERIENCED STRONG DEMAND FOR
PAID
TESTS BASED ON CANCER DIFFERENTIATION ANALYSIS TECHNOLOGY
TECHNOLOGY IN Q1 OF 2021
* ANPAC BIO-MEDICAL SCIENCE CO LTD - CDA-BASED TESTS REACHED
5,439
PAID CANCER TESTS IN Q1, AN ABOUT 130% INCREASE OVER SAME PERIOD
LAST YEAR
Source text for Eikon: ID:nGNX4bbg7z
Further company coverage: ANPC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh2
See all newsBrief: Fresh2 Group On Dec 20, Received Nasdaq Notice That It Will Be Delisted From Nasdaq Capital Market Effective At Open Of Market On Dec 24
Brief: Fresh2 Group Ltd. Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request A Hearing
Brief: Fresh2 Group Ltd Announces Receipt Of A Delinquency Compliance Alert Notice From Nasdaq
Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
Brief: AnPac Bio Granted Continued Listing By Nasdaq Hearing Panel, Subject To Meeting $1 Bid Price Compliance Rule On Or Before Nov. 23, 2022